Revitalizing hope for older adults: The use of the novel Arexvy for immunization against respiratory syncytial virus
Abstract Introduction Respiratory syncytial virus (RSV), an RNA virus of the family Paramyxoviridae, is the most common cause of respiratory tract diseases, including upper and lower respiratory tract infections in adults. Researchers worldwide have been working for decades to develop an RSV vaccine...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-10-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.1648 |
| _version_ | 1797310510868201472 |
|---|---|
| author | Haleema Q. Abbasi Malik O. Oduoye |
| author_facet | Haleema Q. Abbasi Malik O. Oduoye |
| author_sort | Haleema Q. Abbasi |
| collection | DOAJ |
| description | Abstract Introduction Respiratory syncytial virus (RSV), an RNA virus of the family Paramyxoviridae, is the most common cause of respiratory tract diseases, including upper and lower respiratory tract infections in adults. Researchers worldwide have been working for decades to develop an RSV vaccine that is both safe and cost‐effective. Aim This correspondence aims to highlight the recent breakthroughs in the immunization against RSV for older adults (60 years and above), encompassing the newly sanctioned prophylactic agent by the FDA, drawing attention to its side effects that need to be taken care of and providing clear recommendations to maximize the potential influence of these advancements on RSV‐related diseases globally. Methodology We did a literature search on RSV among older adults and its treatment on PubMed, Google Scholar, ResearchGate and FDA databases within 10 years. Keywords used for our search were; “Respiratory Syncytial Virus,” “Older adults,” “FDA,” “Arexvy,” and “Immunization.” Result We found approximately 6000–10,000 lives and 60,000–160,000 hospital admissions among adults aged 65 years and older each year in the world, especially in the United States of America. Currently, there is no vaccine or targeted treatment for RSV for the most affected individuals, that is, the older adults, who are given supportive care. Recently, the USA‐ Food and Drug Administration (FDA) approved Arexvy (a recombinant subunit RSV vaccine) based on its encouraging results demonstrating acceptable safety and efficacy in a large‐scale multi‐centered Phase 3 trial. Conclusion Authorization of Arexvy, although a breakthrough in the field of research, needs to be approached with a blend of optimism tempered by caution. Robust studies, including large‐scale randomized controlled trials, prospective cohort studies and systematic reviews and meta‐analyses, need to be conducted to ascertain its safety and efficacy. |
| first_indexed | 2024-03-08T01:45:03Z |
| format | Article |
| id | doaj.art-3e5f1a017de24bcea1cbd4ffcf2cbb81 |
| institution | Directory Open Access Journal |
| issn | 2398-8835 |
| language | English |
| last_indexed | 2024-03-08T01:45:03Z |
| publishDate | 2023-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Health Science Reports |
| spelling | doaj.art-3e5f1a017de24bcea1cbd4ffcf2cbb812024-02-14T13:06:22ZengWileyHealth Science Reports2398-88352023-10-01610n/an/a10.1002/hsr2.1648Revitalizing hope for older adults: The use of the novel Arexvy for immunization against respiratory syncytial virusHaleema Q. Abbasi0Malik O. Oduoye1Department of Internal Medicine Ayub Medical College Abbottabad PakistanDepartment of Medical Research Circle Bukavu Democratic Republic of CongoAbstract Introduction Respiratory syncytial virus (RSV), an RNA virus of the family Paramyxoviridae, is the most common cause of respiratory tract diseases, including upper and lower respiratory tract infections in adults. Researchers worldwide have been working for decades to develop an RSV vaccine that is both safe and cost‐effective. Aim This correspondence aims to highlight the recent breakthroughs in the immunization against RSV for older adults (60 years and above), encompassing the newly sanctioned prophylactic agent by the FDA, drawing attention to its side effects that need to be taken care of and providing clear recommendations to maximize the potential influence of these advancements on RSV‐related diseases globally. Methodology We did a literature search on RSV among older adults and its treatment on PubMed, Google Scholar, ResearchGate and FDA databases within 10 years. Keywords used for our search were; “Respiratory Syncytial Virus,” “Older adults,” “FDA,” “Arexvy,” and “Immunization.” Result We found approximately 6000–10,000 lives and 60,000–160,000 hospital admissions among adults aged 65 years and older each year in the world, especially in the United States of America. Currently, there is no vaccine or targeted treatment for RSV for the most affected individuals, that is, the older adults, who are given supportive care. Recently, the USA‐ Food and Drug Administration (FDA) approved Arexvy (a recombinant subunit RSV vaccine) based on its encouraging results demonstrating acceptable safety and efficacy in a large‐scale multi‐centered Phase 3 trial. Conclusion Authorization of Arexvy, although a breakthrough in the field of research, needs to be approached with a blend of optimism tempered by caution. Robust studies, including large‐scale randomized controlled trials, prospective cohort studies and systematic reviews and meta‐analyses, need to be conducted to ascertain its safety and efficacy.https://doi.org/10.1002/hsr2.1648Arexvy and immunizationFDAolder adultsrespiratory syncytial virus |
| spellingShingle | Haleema Q. Abbasi Malik O. Oduoye Revitalizing hope for older adults: The use of the novel Arexvy for immunization against respiratory syncytial virus Health Science Reports Arexvy and immunization FDA older adults respiratory syncytial virus |
| title | Revitalizing hope for older adults: The use of the novel Arexvy for immunization against respiratory syncytial virus |
| title_full | Revitalizing hope for older adults: The use of the novel Arexvy for immunization against respiratory syncytial virus |
| title_fullStr | Revitalizing hope for older adults: The use of the novel Arexvy for immunization against respiratory syncytial virus |
| title_full_unstemmed | Revitalizing hope for older adults: The use of the novel Arexvy for immunization against respiratory syncytial virus |
| title_short | Revitalizing hope for older adults: The use of the novel Arexvy for immunization against respiratory syncytial virus |
| title_sort | revitalizing hope for older adults the use of the novel arexvy for immunization against respiratory syncytial virus |
| topic | Arexvy and immunization FDA older adults respiratory syncytial virus |
| url | https://doi.org/10.1002/hsr2.1648 |
| work_keys_str_mv | AT haleemaqabbasi revitalizinghopeforolderadultstheuseofthenovelarexvyforimmunizationagainstrespiratorysyncytialvirus AT malikooduoye revitalizinghopeforolderadultstheuseofthenovelarexvyforimmunizationagainstrespiratorysyncytialvirus |